Emyria Managing Director, Dr Michael Winlo, has had an opinion editorial published in The Canberra Times and selected other media outlets too, titled ‘Psychedelic substances represent a chance to alleviate Australia’s mental health crisis’. In this, he examines the opportunity for supported, learning-based healthcare models to test the merits of psychedelic substances in treating mental health conditions.
We are proud of our data-backed care model at Emyria and Emerald Clinics – which is designed to learn from every single patient and open doors for novel treatments, to address unmet needs.
As featured in the article:
At Emyria, in conjunction with Mind Medicine Australia, we are further working to alleviate the TGA’s concerns and provide the platform to allow patients with major mental health concerns access to these promising new treatments while also support research through the development of an evidence-generating clinical model for psilocybin and MDMA.
The model employs controlled and evidenced-based study protocols, detailed schedules of licensed and validated assessments of clinical and patient-reported outcomes, digital technology, training manuals and data governance frameworks to ensure thorough, quality, best-practice data gathering.